← Leaderboards
Aravinda M De Silva
University Of North Carolina Chapel Hill
$31,411,437
Attributed
$34,105,690
Total exposure
20
Grants
18
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.5M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$34,105,690 · 20
By mechanism
R01$16,997,974 · 4
P01$5,430,134 · 4
U19$4,782,234 · 1
U54$2,359,367 · 4
U24$2,068,146 · 1
R21$993,650 · 2
Top collaborators
- Premkumar Lakshmanane7 shared
- Brian A Kuhlman4 shared
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Mark T Heise$26,876,746
- Ralph S Baric$89,182,261
- Michael W Fried$8,954,521
- Robert E. Johnston$11,943,669
- Philip Frederick Sparling$17,212,219
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionAntibodiesVaccinesSerotypingDengueDengue VirusEpitopesResponseImmunityNeutralizing AntibodyVirusPropertyImmuneAntibody ResponseExposure ToRecombinantsStructureSerumFlavivirusSurfaceSpecificityVirus DiseasesCulicidaeClinical Trials
Grant awards (71)
Structure based design of dengue subunit vaccines for inducing protective but not disease enhancing antibodies$723,184
R01 · FY2025 · AI · contact PI
Project 2: Tetravalent live attenuated dengue virus vaccines: Linkage of vaccine-induced human B cell and antibody response to protective or dengue disease-enhancing immunity$278,006
P01 · FY2025 · AI · contact PI
Project 2: Vaccine Design Epidemic Flaviviruses$4,782,234
U19 · FY2024 · AI · contact PI
Structure based design of dengue subunit vaccines for inducing protective but not disease enhancing antibodies$723,184
R01 · FY2024 · AI · contact PI
Multiplex serological assays to support arbovirus diagnosis, surveillance and vaccines$413,628
U24 · FY2024 · AI · contact PI
PROJECT 2: Linking Vaccine-Induced Antibody Responses to Protective or Disease Enhancing Immunity$406,999
P01 · FY2024 · AI · contact PI
Core B: Shared Resource Core For Characterizing Antibody Responses To SARS-CoV-2 And Other Pathogenic Human Coronaviruses$136,800
U54 · FY2024 · CA · contact PI
Structure based design of dengue subunit vaccines for inducing protective but not disease enhancing antibodies$723,184
R01 · FY2023 · AI · contact PI
Multiplex serological assays to support arbovirus diagnosis, surveillance and vaccines$413,628
U24 · FY2023 · AI · contact PI
PROJECT 2: Linking Vaccine-Induced Antibody Responses to Protective or Disease Enhancing Immunity$406,999
P01 · FY2023 · AI · contact PI
Structure based design of dengue subunit vaccines for inducing protective but not disease enhancing antibodies$723,184
R01 · FY2022 · AI · contact PI
Molecular Basis of Flavivirus Cross-Neutralization by Human Antibodies$571,637
R01 · FY2022 · AI · contact PI
Multiplex serological assays to support arbovirus diagnosis, surveillance and vaccines$413,630
U24 · FY2022 · AI · contact PI
Core B: Shared Resource Core For Characterizing Antibody Responses To SARS-CoV-2 And Other Pathogenic Human Coronaviruses$380,115
U54 · FY2022 · CA · contact PI
PROJECT 2: Linking Vaccine-Induced Antibody Responses to Protective or Disease Enhancing Immunity$376,812
P01 · FY2022 · AI · contact PI
Molecular Basis of Flavivirus Cross-Neutralization by Human Antibodies$571,637
R01 · FY2021 · AI · contact PI
Multiplex serological assays to support arbovirus diagnosis, surveillance and vaccines$413,630
U24 · FY2021 · AI · contact PI
PROJECT 2: Linking Vaccine-Induced Antibody Responses to Protective or Disease Enhancing Immunity$407,000
P01 · FY2021 · AI · contact PI
PRECLINICAL ASSAYS TO PREDICT TETRAVALENT DENGUE VACCINE EFFICACY$1,075,722
R01 · FY2020 · AI · contact PI
Molecular Basis of Flavivirus Cross-Neutralization by Human Antibodies$572,232
R01 · FY2020 · AI · contact PI
Core B: Shared Resource Core For Characterizing Antibody Responses To SARS-CoV-2 And Other Pathogenic Human Coronaviruses$528,796
U54 · FY2020 · CA · contact PI
PROJECT 2: Linking Vaccine-Induced Antibody Responses to Protective or Disease Enhancing Immunity$421,781
P01 · FY2020 · AI · contact PI
Multiplex serological assays to support arbovirus diagnosis, surveillance and vaccines$413,630
U24 · FY2020 · AI · contact PI
PRECLINICAL ASSAYS TO PREDICT TETRAVALENT DENGUE VACCINE EFFICACY$1,080,094
R01 · FY2019 · AI · contact PI
Molecular Basis of Flavivirus Cross-Neutralization by Human Antibodies$573,183
R01 · FY2019 · AI · contact PI
B Cell and Antibody Responses Following Live Attenuated Dengue Virus Vaccination$279,478
P01 · FY2019 · AI · contact PI
PRECLINICAL ASSAYS TO PREDICT TETRAVALENT DENGUE VACCINE EFFICACY$1,082,808
R01 · FY2018 · AI · contact PI
Molecular Basis of Flavivirus Cross-Neutralization by Human Antibodies$587,654
R01 · FY2018 · AI · contact PI
B Cell and Antibody Responses Following Live Attenuated Dengue Virus Vaccination$276,640
P01 · FY2018 · AI · contact PI
Structure based design of recombinant Zika virus antigens for serodiagnosis$194,375
R21 · FY2018 · AI · contact PI
PRECLINICAL ASSAYS TO PREDICT TETRAVALENT DENGUE VACCINE EFFICACY$1,083,712
R01 · FY2017 · AI · contact PI
B Cell and Antibody Responses Following Live Attenuated Dengue Virus Vaccination$1,018,331
P01 · FY2017 · AI · contact PI
Structure based design of recombinant Zika virus antigens for serodiagnosis$233,250
R21 · FY2017 · AI · contact PI
PRECLINICAL ASSAYS TO PREDICT TETRAVALENT DENGUE VACCINE EFFICACY$1,400,997
R01 · FY2016 · AI · contact PI
B Cell and Antibody Responses Following Live Attenuated Dengue Virus Vaccination$1,233,328
P01 · FY2016 · AI · contact PI
Molecular Basis of Dengue Virus Neutralization by Human Antibodies$861,981
R01 · FY2016 · AI · contact PI
Molecular Basis of Dengue Virus Neutralization by Human Antibodies$98,168
R01 · FY2016 · AI · contact PI
Molecular Basis of Dengue Virus Neutralization by Human Antibodies$486,990
R01 · FY2015 · AI · contact PI
B Cell and Antibody Responses Following Live Attenuated Dengue Virus Vaccination$324,760
P01 · FY2015 · AI · contact PI
Molecular Basis of Dengue Virus Neutralization by Human Antibodies$486,964
R01 · FY2014 · AI · contact PI
Molecular Basis of Dengue Virus Neutralization by Human Antibodies$473,049
R01 · FY2013 · AI · contact PI
Antibody in protective and pathogenics immunity to dengue virus serotype 3 DENV3$263,407
U54 · FY2013 · AI · contact PI
Dissecting the Human Antibody Response to Dengue Virus$334,542
R56 · FY2012 · AI · contact PI
Defining Borrelia Genes Required for Tick Infection and Transmission$307,484
R01 · FY2012 · AR · contact PI
Antibody in protective and pathogenics immunity to dengue virus serotype 3 DENV3$271,954
U54 · FY2012 · AI · contact PI
Defining Borrelia Genes Required for Tick Infection and Transmission$307,484
R01 · FY2011 · AR · contact PI
Antibody in protective and pathogenics immunity to dengue virus serotype 3 DENV3$259,631
U54 · FY2011 · AI · contact PI
Defining Borrelia Genes Required for Tick Infection and Transmission$319,272
R01 · FY2010 · AR · contact PI
Antibody in protective and pathogenics immunity to dengue virus serotype 3 DENV3$312,314
U54 · FY2010 · AI · contact PI
Defining Borrelia Genes Required for Tick Infection and Transmission$322,497
R01 · FY2009 · AR · contact PI
Antibody in protective and pathogenics immunity to dengue virus serotype 3 DENV3$138,388
U54 · FY2009 · AI · contact PI
Defining Borrelia Genes Required for Tick Infection and Transmission$321,607
R01 · FY2008 · AR · contact PI
Monoclonal Antibodies for Dengue Virus$67,962
U54 · FY2008 · AI · contact PI
Risk Factors for Dengue Hemorrhagic Fever in Sri Lanka$34,735
R03 · FY2008 · TW · contact PI
Anti-Complement Proteins of Ixodes Scapularis$153,722
U01 · FY2007 · AI · contact PI
Risk Factors for Dengue Hemorrhagic Fever in Sri Lanka$34,881
R03 · FY2007 · TW · contact PI
Population dynamics of Borrelia transmitted by ticks$284,586
R01 · FY2006 · AR · contact PI
Anti-Complement Proteins of Ixodes Scapularis$153,084
U01 · FY2006 · AI · contact PI
Risk Factors for Dengue Hemorrhagic Fever in Sri Lanka$35,961
R03 · FY2006 · TW · contact PI
Population dynamics of Borrelia transmitted by ticks$291,435
R01 · FY2005 · AR
Interactions between dengue 3 and human dendritic cells$284,252
R21 · FY2005 · AI
Anti-Complement Proteins of Ixodes Scapularis$152,851
U01 · FY2005 · AI
Population dynamics of Borrelia transmitted by ticks$315,857
R01 · FY2004 · AR
Interactions between dengue 3 and human dendritic cells$281,773
R21 · FY2004 · AI
Anti-Complement Proteins of Ixodes Scapularis$148,400
U01 · FY2004 · AI
Population dynamics of Borrelia transmitted by ticks$315,857
R01 · FY2003 · AR
Anti-Complement Proteins of Ixodes Scapularis$72,039
U01 · FY2003 · AI
Population dynamics of Borrelia transmitted by ticks$312,331
R01 · FY2002 · AR
GENE EXPRESSION BY TICK TRANSMITTED BORRELIA BURGDORFERI$117,990
K01 · FY2002 · AR
GENE EXPRESSION BY TICK TRANSMITTED BORRELIA BURGDORFERI$117,990
K01 · FY2001 · AR
GENE EXPRESSION BY TICK TRANSMITTED BORRELIA BURGDORFERI$117,990
K01 · FY2000 · AR